Trade Resources Industry Views Astellas Pharma US Has Launched ASTAGRAF XL

Astellas Pharma US Has Launched ASTAGRAF XL

Astellas Pharma US has launched ASTAGRAF XL (tacrolimus extended-release capsules), the first once-daily oral tacrolimus formulation, in the US market.

The new product is indicated for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.

Astellas Pharma US president James Robinson said the availability of ASTAGRAF XL marks a significant moment for the transplantation community, giving new adult kidney transplant recipients an additional option in their immunosuppressant care.

"Astellas has long been a leader in the field of transplant immunology, and we are proud to continue to advance care for transplant recipients," Robinson added.

A 0.15mg/kg once-daily (pre-operative) and 0.2mg/kg once-daily (post-operative) are recommended starting dose of ASTAGRAF XL with basiliximab induction.

The product is available in 0.5mg, 1mg and 5mg capsules.

 

Source: http://drugdiscovery.pharmaceutical-business-review.com/news/astellas-pharma-launches-once-daily-oral-tacrolimus-formulation-in-us-230813
Contribute Copyright Policy
Astellas Pharma Launches Once-Daily Oral Tacrolimus Formulation in US